Sai Parenterals Q2 Revenue Hits Rs 194.92 Crore; Expands Portfolio

Sai Parenterals reported revenue of Rs 194.92 crore for Q2 FY2027, up significantly from Rs 53.53 crore in the year-ago period.
Profit after tax rose 65.5% to Rs 10.51 crore compared to Rs 6.35 crore in Q2 FY2026.

Reader Takeaway: Strong revenue growth and strategic acquisitions drive expansion, though operational integration of new subsidiaries remains a key focus.

What just happened

The board of Sai Parenterals met on November 1, 2026, to review financial results and approve corporate restructuring. The company revealed it has completed the 60% acquisition of Saicriti Pharma Private Limited. Furthermore, the board greenlit plans to acquire the remaining 25% stake in SP Analytics Private Limited, effectively turning it into a wholly-owned subsidiary by the end of December 2026. A new Management Committee has also been formed to oversee operational efficiency.

Why this matters

The triple-digit percentage growth in revenue signals a significant scale-up in business operations compared to the previous fiscal year. By consolidating its hold on SP Analytics and integrating Saicriti Pharma, the company is positioning itself for a broader market reach in the pharmaceutical space. The newly formed Management Committee, chaired by MD Anil Kumar Karusala, aims to streamline decision-making as these entities are brought under the core business framework.

What changes now

Investors will see the full financial impact of SP Analytics once it becomes a 100% subsidiary. The company is transitioning from a period of aggressive acquisition to operational integration. Shareholders should track the synergy benefits from the Saicriti Pharma deal and the performance contributions from the newly formed Management Committee in upcoming quarters.

Context metrics (Q2 FY2027)

• Consolidated Revenue: Rs 194.92 crore (+264% YoY)
• Consolidated PAT: Rs 10.51 crore (+65.5% YoY)
• SP Analytics: Remaining 25% stake acquisition scheduled for completion by Dec 31, 2026.

What to track next

The market will look for details on how the newly acquired entities contribute to profit margins and whether the management committee delivers the intended operational efficiencies.